236 related articles for article (PubMed ID: 2920501)
1. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
Simpson GM; Gratz SS
Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
[TBL] [Abstract][Full Text] [Related]
5. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
Cusson JR; Goldenberg E; Larochelle P
J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
[TBL] [Abstract][Full Text] [Related]
6. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
Bieck PR; Antonin KH
J Clin Psychopharmacol; 1988 Aug; 8(4):237-45. PubMed ID: 3209716
[TBL] [Abstract][Full Text] [Related]
7. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
Bieck PR; Antonin KH
J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
[TBL] [Abstract][Full Text] [Related]
8. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
Bieck PR
Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
[TBL] [Abstract][Full Text] [Related]
9. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Celada P; Pérez J; Alvarez E; Artigas F
J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
[TBL] [Abstract][Full Text] [Related]
11. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
Dyck LE; Boulton AA
Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
[TBL] [Abstract][Full Text] [Related]
12. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Waldmeier PC
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
Bieck PR; Antonin KH; Schmidt E
Clin Neuropharmacol; 1993; 16 Suppl 2():S34-41. PubMed ID: 8313395
[TBL] [Abstract][Full Text] [Related]
14. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.
Kennedy SH; Davis BA; Brown GM; Ford CG; d'Souza J
Neurochem Res; 1993 Dec; 18(12):1281-5. PubMed ID: 7505890
[TBL] [Abstract][Full Text] [Related]
16. Tyramine infusions and selective monoamine oxidase inhibitor treatment. II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction.
Pickar D; Cohen RM; Jimerson DC; Lake CR; Murphy DL
Psychopharmacology (Berl); 1981; 74(1):8-12. PubMed ID: 6791210
[TBL] [Abstract][Full Text] [Related]
17. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
18. Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine.
Waldmeier PC; Graf T; Germer M; Feldtrauer JJ; Howald H
Biol Psychiatry; 1993 Mar; 33(5):373-9. PubMed ID: 8471696
[TBL] [Abstract][Full Text] [Related]
19. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.
Davis BA; Kennedy SH; Durden DA; D'Souza J; Goldbloom DS; Boulton AA
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Sep; 17(5):747-63. PubMed ID: 7504824
[TBL] [Abstract][Full Text] [Related]
20. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
